<DOC>
	<DOCNO>NCT01031667</DOCNO>
	<brief_summary>The purpose study evaluate effect combination therapy cilostazol probucol plaque volume composition change comparison cilostazol alone serial intravascular ultrasound virtual histology .</brief_summary>
	<brief_title>Synergistic Effect Combination Therapy With Cilostazol Probucol Plaque Stabilization Lesion Regression : Serial Intravascular Ultrasound Virtual Histology Study ( SECURE Study )</brief_title>
	<detailed_description />
	<mesh_term>Cilostazol</mesh_term>
	<mesh_term>Probucol</mesh_term>
	<criteria>1 . Patients treat PCI stent 2 . Male female 20 year age 3 . Presence least one PCI target lesion ( lesion length ≤26mm ) ≥50 % diameter stenosis cover single Endeavor Sprint stent ( Medtronic ) 4 . Other PCI target lesion also treat Endeavor Sprint stents 5 . Presence intermediate nonPCI target lesion luminal narrowing ≥30 % ≤70 % visual estimation 6 . Signed write informed consent participate study 1 . Intermediate ( nonPCI target ) lesion might provide difficulty IVUS evaluation follow reason : heavy calcification ( &gt; 90° Arc ) , tortuous vessel sever angulation , total occlusion , bifurcation lesion 2 . Previous PCI last 6 month 3 . Previous CABG 4 . Patients AMI undergoing primary PCI rescue PCI thrombolysis 5 . Cardiogenic shock 6 . Inability take adequate antiplatelet therapy 7 . Thrombocytopenia ( platelet count &lt; 70 x 109/l ) 8 . Known hypersensitivity contraindication follow medication : Heparin , aspirin , clopidogrel , cilostazol , probucol , statin , contrast media* *Patients document sensitivity contrast medium effectively premedicated steroid diphenhydramine [ e.g . rash ] may enrol . Those true anaphylaxis prior contrast medium , however , enrol . 9 . History severe ventricular arrhythmia 10 . Significant QTc prolongation ( ≥470 m ) ECG 11 . NYHA class III/IV heart failure LV ejection fraction ≤35 % 12 . Familial hypercholesterolemia 13 . Uncontrolled hypertriglyceridemia ( &gt; 400 mg/dL ) 14 . Chronic renal failure serum creatinine level ≥2mg/dL 15 . Severe liver disease transaminase level ≥3 time upper limit normal . 16 . Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Patients treat PCI stent</keyword>
</DOC>